Pathologische Frakturen des Humerus: Erfahrungen an 76 Fällen eines muskuloskeletalen Tumorzentrums

Abstract

The demographic transition - with an increasing number of malignancies on the one hand and improved life expectancy under modern, adjuvant therapies on the other - will become a challenge in the treatment of pathological fractures of the humerus for a variety of disciplines.

Treating pathological metastatic fractures of the humerus by compound osteosynthesis: a retrospective cohort study

“…The most common tumor entities responsible for a pathological fracture were renal cell and breast carcinoma, accounting for 33% of all pathological fractures in their cohort. 20 Piccioli et al disclosed a mean survival of 8.3 months after surgery for pathological humeral fractures in 87 cases. In 39% of those cases, breast carcinoma or renal cell carcinoma was the primary tumor.…”

“… 4 The number of patients reaching the metastatic stage is steadily increasing due to the aging population and advanced oncological therapies. 20 Although some cancers, such as renal cell, breast, or prostate cancer, preferentially metastasize to bone, virtually any malignancy has the potential to develop bone metatases. 3 , 12 Osseous metastases are most commonly spread through hematogenous dissemination.…”